Bladder carcinoma: understanding advanced and metastatic disease with potential molecular therapeutic targets

References

• Cancer Research UK. Cancer Stats. (2002).
   Google Scholar
• Jemal A, Thomas A, Murray T, Thun M. Cancer Statistics 2002. CA Cancer J. Clin. 52, 23–47 (2002).
   PubMed Web of Science ®Google Scholar
• ONS Report. Registrations of cancer diagnosed in 1993–1996, England and Wales. Health Statistics Quarterly. Office for National Statistics, London, UK (1999).
   Google Scholar
• Cancer statistics registration: OPCS – a publication of the Government Statistical Service. OPCS (2001).
   Google Scholar
• Lutzeyer W, Rubben H, Dahm H. Prognostic parameters in superficial bladder cancer: an analysis of 315 cases. J. Urol. 127, 250–252 (1982).
   PubMed Web of Science ®Google Scholar
• Duggan BJ, Gray SB, McKnight JJ et al. Oligoclonality in bladder cancer: the implication for molecular therapies. J. Urol. 171, 419–425 (2004).
   PubMed Web of Science ®Google Scholar
• Garcia SB, Park HS, Novelli M, Wright NA. Field characterisation, clonality, and epithelial stem cells: the spread of mutated clones in epithelial sheets. J. Pathol. 187, 61–81 (1999).
   PubMedGoogle Scholar
• Sidransky D, Frost P, von Eschenbach A, Oyasu Y, Preisinger AC, Vogelstein B. Clonal origin of bladder cancer. N. Eng. J. Med. 326, 737–740 (1992).
   PubMed Web of Science ®Google Scholar
• Hafner C, Knuechel R, Stoehr R, Hartmann A. Clonality of multifocal urothelial carcinomas: 10 years of molecular genetic studies. Int. J. Cancer 101(1), 1–6 (2002).
   PubMed Web of Science ®Google Scholar
• Stoehr R, Knuechel R, Boecker J et al. Histologic-genetic mapping by allele-specific PCR reveals intraurothelial spread of p53 mutant tumour clones. Lab. Invest. 82(11), 1553–1561 (2002).
   PubMedGoogle Scholar
• Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 100, 57–70 (2000).
   PubMed Web of Science ®Google Scholar
• Babaian RJ, Johnson DE, Llamas L, Ayala AG. Metastases from transitional cell carcinoma of urinary bladder. Urology 16(2), 142–144 (1980).
   PubMed Web of Science ®Google Scholar
• Sandberg AA, Berger CS. Review of chromosome studies in urologic tumors. II. Cytogenetic and molecular genetics of bladder cancer. J. Urol. 151, 545–560 (1994).
   PubMed Web of Science ®Google Scholar
• Hirao S, Hirao T, Marsit CJ et al. Loss of heterozygosity on chromosome 9q and p53 alterations in human bladder cancer. Cancer (2005) (In Press).
   Google Scholar
• Presti JC Jr, Reuter VE, Galan T, Fair WR, Cordon-Cardo C. Molecular genetic alterations in superficial and locally advanced human bladder cancer. Cancer Res. 51, 5405–5409 (1991).
   PubMed Web of Science ®Google Scholar
• Olumi AF, Tsai YC, Nichols PW et al. Allelic loss of chromosome 17p distinguishes high grade from low grade transitional cell carcinomas of the bladder. Cancer Res. 50, 7081–7083 (1990).
   PubMed Web of Science ®Google Scholar
• Akiyama T, Sudo C, Ogawara H, Toyoshima K, Yamamoto T. The product of the human c-erbB-2 gene: a 185-kilodalton glycoprotein with tyrosine kinase activity. Science 232, 1644–1646 (1986).
   PubMed Web of Science ®Google Scholar
• Sato K, Moriyama M, Mori S et al. An immunohistologic evaluation of C-erbB-2 gene product in patients with urinary bladder carcinoma. Cancer 70, 2493 (1992).
   Google Scholar
• Neal DE, Sharples L, Smith K et al. Epidermal growth-factor receptors in human bladder cancer: comparison of invasive and superficial tumours. Lancet 1, 366–368 (1985).
   PubMed Web of Science ®Google Scholar
• Messing EM. Clinical implications of the expression growth factor receptors in human transitional cell carcinomas. Cancer Res. 50, 2530–2537 (1990).
   PubMed Web of Science ®Google Scholar
• Sauter G, Moch D, Moore P et al. Heterogeneity of erbB-2 gene amplification in bladder cancer. Cancer Res. 53, 2199–2203 (1993).
   PubMed Web of Science ®Google Scholar
• Miyamoto H, Kubota Y, Noguchi S et al. C-ERBB-2 gene amplification as a prognostic marker in human bladder cancer. Urology 55, 679–683 (2000).
   PubMed Web of Science ®Google Scholar
• Al-Sukhun S, Hussain M. Current understanding of the biology of advanced bladder cancer. Cancer 97(Suppl. 8), 2064–2075 (2003).
   PubMedGoogle Scholar
• Bue P, Wester K, Sjostrom A et al. Expression of epidermal growth factor receptor in urinary bladder cancer metastases. Int. J. Cancer. 76, 189–193 (1998).
   PubMed Web of Science ®Google Scholar
• Latif Z, Watters AD, Dunn I, Grigor K, Underwood MA, Bartlett JM. HER2/neu gene amplification and protein overexpression in G3 pT2 transitional cell carcinoma of the bladder: a role for anti-HER2 therapy? Eur. J. Cancer 40(1), 56–63 (2004).
   PubMed Web of Science ®Google Scholar
• Vieillefond A, Beuzeboc P, Mignot L et al. HER2 status in urolthelial bladder cancer (UC): screening of patients eligible for a phase II randomised study of gencitabine plus platinum salt with or without trastuzumab. 2005 ASCO Annual Meeting Proceedings. J. Clin. Oncology 23(16S), 4696 (2005).
   Google Scholar
• Hussain M, Petrylak D, Dunn R et al. Trastuzumab (T), paclitaxel (P), carboplatin (C), gemcitabine (G) in advanced HER2-positive urothelial carcinoma: results of a multi-center phase II NCI trial. 2005 ASCO Annual Meeting Proceedings. J. Clin. Oncology 23(16S), 4507 (2005).
   Google Scholar
• Dominguez-Escrig JL, Kelly JD, Neal DE, King SM, Davies BR. Evaluation of the therapeutic potential of the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib in preclinical models of bladder cancer. Clin. Cancer Res. 10(14), 4874–4884 (2004).
   PubMed Web of Science ®Google Scholar
• Bellmunt J, Hussain M, Dinney CP. Novel approaches with targeted therapies in bladder cancer. Therapy of bladder cancer by blockade of the epidermal growth factor receptor family. Crit. Rev. Oncol. Hematol. 46(Suppl.), S85–S104 (2003).
   PubMedGoogle Scholar
• Small EJ, Halabi S, Dalbagni Gb et al. Cancer and Leukemia Group B. Overview of bladder cancer trials in the Cancer and Leukemia Group B. Cancer 97(Suppl. 8), 2090–2098 (2003).
   PubMed Web of Science ®Google Scholar
• Scholl S, Beuzeboc P, Pouillart P. Targeting HER2 in other tumor types. Ann. Oncol. 12(Suppl. 1), S81–S87 (2001).
   PubMedGoogle Scholar
• McHugh LA, Griffiths TR, Kriajevska M, Symonds RP, Mellon JK. Tyrosine kinase inhibitors of the epidermal growth factor receptor as adjuncts to systemic chemotherapy for muscle-invasive bladder cancer. Urology 63(4), 619–624 (2004).
   PubMedGoogle Scholar
• Machiels JP, Wulfing C, Richel DJ et al. A single arm, multicenter, open-label phase II study of orally administered GW572016 as single-agent, second-line treatment of patients with locally advanced or metastatic transitional cell carcinoma of the urothelial tract. Interim analysis. 2004 ASCO Annual Meeting Proceedings. J. Clin. Oncology 22(Suppl. 14), 4614 (2004).
   Google Scholar
• Wulfing C, Machiels JP, Richel D et al. A single arm , multicenter, open label, phase II study of lapatinib as 2L treatment of pts with locally advanced/metastatic transitional cell carcinoma (TCC) of the urothelial tract. 2005 ASCO Annual Meeting Proceedings. J. Clin. Oncology 23(Suppl. 16), 4594 (2005).
   Web of Science ®Google Scholar
• Philips G, Halbi S, Sanford B, Bajorin D, Small E. Phase II trial of Cisplatin©, fixed-dose gemcitabine (G) and gefitinib for advanced transitional cell carcinoma (TCC) of the urothelial tract: preliminary results of CALGB 90102. 2004 ASCO Annual Meeting Proceedings. J. Clin. Oncology 22(14S), 4538 (2004).
   Google Scholar
• Hussain SA, Ganesan R, Hiller L et al. BCL2 expression predicts survival in patients receiving synchronous chemoradiotherapy in advanced transitional cell carcinoma of the bladder. Oncol. Reports 10, 571–576 (2003).
   PubMed Web of Science ®Google Scholar
• Cooke PW, James ND, Ganesan R, Burton A, Young LS, Wallace DM. Bcl-2 expression identifies patients with advanced bladder cancer treated by radiotherapy who benefit from neoadjuvant chemotherapy. Br. J. Urol. Int. 85, 829–835 (2000).
   Google Scholar
• Shiina H, Igawa M, Urakami S, Honda S, Shirakawa H, Ishibe T. Immunohistochemical analysis of bcl-2 expression in transitional cell carcinoma of the bladder. J. Clin. Pathol. 49, 395–399 (1995).
   Google Scholar
• Asci R, Yildiz L, Sarikaya S, Buyukalpelli R, Yilmaz AF, Kandemir B. p53 and bcl-2 overexpression as associated risk factors in patients 40 years old or less with transitional cell carcinoma of the bladder. Urol. In. 67, 34–40 (2001).
   Google Scholar
• Pollack A, Wu CS, Czerniak B, Zagars GK, Benedict WF, McDonnell TJ. Abnormal bcl-2 and pRb expression are independent correlates of radiation response in muscle-invasive bladder cancer. Clin. Cancer Res. 3, 1823–1829 (1997).
   PubMedGoogle Scholar
• Rodel C, Grabenbauer GG, Rodel F et al. Apoptosis, p53, bcl-2, and Ki-67 in invasive bladder carcinoma: possible predictors for response to radiochemotherapy and successful bladder preservation. Int. J. Radiat. Oncol. Biol. Phys. 46, 1213–1221 (2000).
   PubMed Web of Science ®Google Scholar
• Schaaf A, Sagi S, Langbein S, Trojan L, Alken P, Michel MS. Cytotoxicity of cisplatin in bladder cancer is significantly enhanced by application of bcl-2 antisense oligonucleotides. Urol. Oncol. 22(3), 188–192 (2004).
   PubMed Web of Science ®Google Scholar
• Klasa RJ, Gillum AM, Klem RE, Frankel SR. Oblimersen Bcl-2 antisense: facilitating apoptosis in anticancer treatment. Antisense Nucleic Acid Drug Dev. 12(3), 193–213 (2002).
   PubMedGoogle Scholar
• Gohji K, Nomi M, Niitani Y et al. Independent prognostic value of serum hepatocyte growth factoring bladder cancer. J. Clin. Oncol. 18, 2963–2971 (2000).
   PubMedGoogle Scholar
• Tamatani T, Hattori K, Iyer A, Tamatani K, Oyasu Y. Hepatocyte growth factor is an invasion/migration factor of rat urothelial carcinoma cells in vitro. Carcinogenesis 20, 957–962 (1999).
   PubMedGoogle Scholar
• Cheng HL, Liu HS, Lin YJ et al. Co-expression of RON and MET is a prognostic indicator for patients with transitional-cell carcinoma of the bladder. Br. J. Cancer 92(10), 1906–1914 (2005).
   PubMed Web of Science ®Google Scholar
• Cheng HL, Trink B, Tzai TS et al. Overexpression of c-met as a prognostic indicator for transitional cell carcinoma of the urinary bladder: a comparison with p53 nuclear accumulation. J. Clin. Oncol. 20(6), 1544–1550 (2002).
   PubMed Web of Science ®Google Scholar
• Oxford G, Theodorescu D. The role of Ras superfamily proteins in bladder cancer progression. J. Urol. 170, 1987–1993 (2003).
   PubMed Web of Science ®Google Scholar
• Haliassos A, Liloglou M, Likourinas M, Doumas C, Ricci N, Spandidos DA. H-ras oncogene mutations in the urine of patients with bladder tumours: description of a novel non-invasive method for the detection of neoplasia. Int. J. Oncol. 1, 731–734 (1991).
   Google Scholar
• Przybojewska B, Jagiello A, Jalmuzna P. H-RAS, K-RAS, and N-RAS gene activation in human bladder cancers. Cancer Genet. Cytogenet. 121, 73–77 (2000).
   PubMed Web of Science ®Google Scholar
• Sarkis AS, Dalbagni G, Cordon C et al. Nuclear overexpression of p53 protein in transitional cell carcinoma: a marker for disease progression. J. Natl Cancer Inst. 85, 53–59 (1993).
   PubMed Web of Science ®Google Scholar
• Malats N, Bustos A, Nascimento CM et al. P53 as a prognostic marker for bladder cancer: a meta-analysis and review. Lancet Oncol. 6(9), 678–86 (2005).
   PubMed Web of Science ®Google Scholar
• Sridhar SS, Stadler L, Le L et al. Phase II study of bortezomib in advanced or metastatic urothelial cancer. A trial of the Princess Margaret Hospital (PMH) Phase II consortium. 2005 ASCO Annual Meeting Proceedings. J. Clin. Oncology 23(16S), 4677 (2005).
   Web of Science ®Google Scholar
• Kamat AM, Karashima T, Davis DW et al. The proteasome inhibitor bortezomib synergizes with gemcitabine to block the growth of human 253JB-V bladder tumors in vivo. Mol. Cancer Ther. 3(3), 279–290 (2004).
   PubMed Web of Science ®Google Scholar
• Smith ND, Rubensten JN, Eggener SE, Kozlowski JM. The p53 tumor suppressor gene and nuclear protein: basic science review and relevance in the management of bladder cancer. J. Urol. 169(4), 1219–1228 (2003).
   PubMed Web of Science ®Google Scholar
• Miyake H, Yamanaka K, Muramaki M, Hara I, Gleave ME. Therapeutic efficacy of adenoviral-mediated p53 gene transfer is synergistically enhanced by combined use of antisense oligodeoxynucleotide targeting clusterin gene in a human bladder cancer model. Neoplasia 7(2), 171–179 (2005).
   PubMed Web of Science ®Google Scholar
• Pagliaro LC, Keyhani A, Liu B, Perrotte P, Wilson D, Dinney CP. Adenoviral p53 gene transfer in human bladder cancer cell lines: cytotoxicity and synergy with cisplatin. Urol. Oncol. 21(6), 456–462 (2003).
   PubMed Web of Science ®Google Scholar
• Zhu Z, Xing S, Lin C et al. Bladder cancer therapy using combined proliferating cell nuclear antigen antisense oligonucleotides and recombinant adenovirus p53. Chin. Med. J. (Engl) 116(12), 1860–1863 (2003).
   PubMedGoogle Scholar
• Logothetis CJ, Xu HJ, Ro JY et al. Altered expression of the retinoblastoma gene product: prognostic indicator in bladder cancer. J. Natl Cancer Inst. 84, 1251–1256 (1992).
   PubMedGoogle Scholar
• Cordon-Cardo C. Mutations of cell cycle regulators. Biological and clinical implications for human Neoplasia. Am. J. Pathol. 147, 545–560 (1995).
   PubMed Web of Science ®Google Scholar
• Quentin T, Henke C, Korabiowska M, Schlott T, Zimmerman B, Kunze E. Altered mRNA expression of the Rb and p16 tumor suppressor genes and of CDK4 in transitional cell carcinomas of the urinary bladder associated with tumor progression. AntiCancer Res. 24(2B), 1011–1023 (2004).
   PubMedGoogle Scholar
• Xu HJ, Zhou Y, Seigne J et al. Enhanced tumor suppressor gene therapy via replication-deficient adenovirus vectors expressing an N-terminal truncated retinoblastoma protein. Cancer Res. 56(10), 2245–2249 (1996).
   PubMed Web of Science ®Google Scholar
• Streeter EH, Harris AL. Angiogenesis in bladder cancer – prognostic marker and target for future therapy. Surg. Oncol. 11, 85–100 (2002).
   PubMedGoogle Scholar
• Bochner BH, Cote RJ, Weidner N et al. Angiogenesis in bladder cancer: relationship between microvessel density and tumor prognosis. J. Natl Cancer Inst. 87, 1603–1612 (1995).
   PubMed Web of Science ®Google Scholar
• Jaeger TM, Weidner N, Chew K et al. Tumor angiogenesis correlates with lymph node metastases in invasive bladder cancer. J. Urol. 154, 69–71 (1995).
   PubMed Web of Science ®Google Scholar
• Grothey A. Antiangiogenic therapy in cancer: a new era has begun. Oncology 19(4 Suppl. 3), 5–6 (2005).
   PubMedGoogle Scholar
• Crew JP, O’Brien T, Bicknell R, Fuggle S, Cranston D, Harris AL. Urinary vascular endothelial growth factor and its correlation with bladder cancer recurrence rates. J. Urol. 161, 799–804 (1999).
   PubMed Web of Science ®Google Scholar
• Williams SG, Feng A, Skinner DG. Urine levels of vascular endothelial growth factor and its correlation with bladder cancer recurrence rate. J. Urol. 162, 133 (2000).
   Google Scholar
• Yang CC, Chu KC, Yeh WM. The expression of vascular endothelial growth factor in transitional cell carcinoma of urinary bladder is correlated with cancer progression. Urol. Oncol. 22(1), 1–6 (2004).
   PubMed Web of Science ®Google Scholar
• Suzuki K, Morita T, Tokue A. Vascular endothelial growth factor-C (VEGF-C) expression predicts lymph node metastasis of transitional cell carcinoma of the bladder. Int. J. Urol. 12(2), 152–158 (2005).
   PubMed Web of Science ®Google Scholar
• Slaton JW, Millikan R, Inoue K et al. Correlation of metastasis related gene expression and relapse-free survival in patients with locally advanced bladder cancer treated with cystectomy and chemotherapy. J. Urol. 171(2), 570–574 (2004).
   PubMed Web of Science ®Google Scholar
• Davis DW, Inoue K, Dinney CP, Hicklin DJ, Abbruzzese JL, McConkey DJ. Regional effects of an antivascular endothelial growth factor receptormonoclonal antibody on receptor phosphorylation and apoptosis in human 253J B-Vbladder cancer xenografts. Cancer Res. 64(13), 4601–4610 (2004).
   PubMed Web of Science ®Google Scholar
• Brown NS, Streeter EH, Jones A, Harris AL, Bicknell R. Cooperative stimulation of vascular endothelial growth factor expression by hypoxia and reactive oxygen species: the effect of targeting vascular endothelial growth factor and oxidative stress in an orthotopic xenograft model of bladder carcinoma. Br. J. Cancer. 92(9), 1696–1670 (2005).
   PubMed Web of Science ®Google Scholar
• Rhee J, Hoff PM. Angiogenesis inhibitors in the treatment of cancer. Expert Opin. Pharmacother. 6(10), 1701–1711 (2005).
   PubMed Web of Science ®Google Scholar
• Krause S, Forster Y, Kraemer K et al. Vascular endothelial growth factor antisense pretreatment of bladder cancer cells significantly enhances the cytotoxicity of mitomycin C, gemcitabine and cisplatin. J. Urol. 174(1), 328–331 (2005).
   PubMed Web of Science ®Google Scholar
• Takei S, Iseda T, Yokoyama M. Inhibitory effect of clotrimazole on angiogenesis associated with bladder epithelium proliferation in rats. Int. J. Urol. 10(2), 78–85 (2003).
   PubMed Web of Science ®Google Scholar
• Gazzaniga P, Gandini O, Gradilone A et al. Detection of basic fibroblast factor mRNA in urinary bladder cancer: correlation with local relapses. Int. J. Oncol. 14, 1123–1127 (1999).
   PubMed Web of Science ®Google Scholar
• Nguyen M, Watanabe H, Budson A, Richie J, Folkman J. Elevated levels of the angiogenic peptide basic fibroblast growth factor in urine of bladder cancer patients. J. Natl Cancer Inst. 85, 241–242 (1993).
   PubMed Web of Science ®Google Scholar
• Miyake H, Hara I, Gohji K, Yoshimura K, Arakawa S, Kamidono S. Expression of basic fibroblast growth factor is associated with resistance to cisplatin in a human bladder cancer cell line. Cancer Lett. 123(2), 121–126 (1998).
   PubMed Web of Science ®Google Scholar
• Inoue K, Perrotte P, Wood CG, Slaton JW, Sweeney P, Dinney CP. Gene therapy of human bladder cancer with adenovirus-mediated antisense basic fibroblast growth factor. Clin. Cancer Res. 6(11), 4422–4431 (2000).
   PubMed Web of Science ®Google Scholar
• Kim SI, Kwon SM, Kim YS, Hong SJ. Association of cyclooxygenase-2 expression with prognosis of stage T1 grade 3 bladder cancer. Urology 60, 816–821 (2002).
   PubMedGoogle Scholar
• Wild PJ, Kunz-Schughart LA, Stoehr R et al. High-throughput tissue microarray analysis of COX2 expression in urinary bladder cancer. Int. J. Oncol. 27(2), 385–391 (2005).
   PubMed Web of Science ®Google Scholar
• Wadhwa P, Goswami AK, Joshi K, Sharma SK. Cyclooxygenase-2 expression increases with the stage and grade in transitional cell carcinoma of the urinary bladder. Int. Urol. Nephrol. 37(1), 47–53 (2005).
   PubMedGoogle Scholar
• Thun MJ, Henley SJ, Patrono C. Nonsteroidal anti-inflammatory drugs as anticancer agents. Mechanistic, pharmacologic, and clinical issues. J. Natl Cancer Inst. 94, 252–266 (2002).
   PubMed Web of Science ®Google Scholar
• Dovedi SJ, Kirby JA, Atkins H, Davies BR, Kelly JD. Cyclooxygenase-2 inhibition: a potential mechanism for increasing the efficacy of bacillus calmette-guerin immunotherapy for bladder cancer. J. Urol. 174(1), 332–337 (2005).
   PubMed Web of Science ®Google Scholar
• Mizutani Y, Okada Y, Yoshida O. Expression of platelet-derived endothelial cell growth factor in bladder carcinoma. Cancer 79, 1190–1194 (1997).
   PubMed Web of Science ®Google Scholar
• Inoue K, Slaton JW, Perrotte P et al. Inteleukin-8 expression regulates tumorigenicity and metastasis in human bladder cancer. Cancer Res. 60, 2290–2299 (2000).
   PubMed Web of Science ®Google Scholar
• Grossfield GD, Ginsberg DA, Stein JP et al. Thrombospondin-1 expression in bladder cancer: association with p53 alterations, tumor angiogenesis, and tumor progression. J. Natl Cancer Inst. 89, 219–227 (1997).
   PubMedGoogle Scholar
• Goddard JC, Sutton CD, Jones JL, O'Byrne KJ, Kockelbergh RC. Reduced thrombospondin-1 at presentation predicts disease progression in superficial bladder cancer. Eur. Urol. 42(5), 464–468 (2002).
   PubMedGoogle Scholar
• Karyekar CS, Carr RA, Andre A et al. Pharmacokinetics (PK) of the angiogenesis inhibitor ABT-510 in healthy subjects. 2004 ASCO Annual Meeting Proceedings. J. Clin. Oncology 22(14S), 3080 (2004).
   PubMedGoogle Scholar
• Reiher FK, Volpert OV, Jimenez B et al. Inhibition of tumor growth by systemic treatment with thrombospondin-1 peptide mimetics. Int. J. Cancer 98(5), 682–689 (2002).
   PubMed Web of Science ®Google Scholar
• Du Z, Hou S. The anti-angiogenic activity of human endostatin inhibits bladder cancer growth and its mechanism. J. Urol. 170(5), 2000–2003 (2003).
   PubMed Web of Science ®Google Scholar
• Syrigos KN, Harrington KJ, Pignatelli M. Role of adhesion molecules in bladder cancer: an important part of the jigsaw. Urology 53(2), 428–434 (1999).
   PubMed Web of Science ®Google Scholar
• Jankowski JA, Bruton R, Shepherd N, Sanders DSA. Cadherin and catenin biology represent a global mechanism for epithelial cancer progression. J. Clin. Pathol. Mol. Pathol. 50, 289–290 (1997).
   Google Scholar
• Price JT, Thompson EW. Mechanisms of tumour invasion and metastasis: emerging targets for therapy. Expert Opin. Ther. Targets. 6(2), 217–233 (2002).
   PubMedGoogle Scholar
• Okegawa T, Pong RC, Li Y, Hsieh JT. The role of cell adhesion molecule in cancer progression and its application in cancer therapy. Acta Biochim. Pol. 51(2), 445–457 (2004).
   PubMed Web of Science ®Google Scholar
• Mialhe A, Louis J, Montlevier S et al. Expression of E-cadherin and α-, β- and γ-catenins in human bladder carcinomas: are they good prognostic factors? Invasion Metastasis 17, 124–137 (1997).
   PubMedGoogle Scholar
• Giroldi LA, Bringuier PP, Shimazui T, Jansen K, Schalken JA. Changes in cadherin-catenin complexes in the progression of human bladder carcinoma. Int. J. Cancer 82, 70–76 (1992).
   Google Scholar
• Mialhe A, Levacher G, Champelovier P et al. Expression of E-, P-, n-cadherins and catenins in human bladder carcinoma cell lines. J. Urol. 164(3), 826–835 (2000).
   PubMedGoogle Scholar
• Nakopoulou L, Zervas A, Gakiopoulou-Givalou H et al. Prognostic value of E-cadherin, b-catenin, P120ctn in patients with transitional cell bladder cancer. AntiCancer Res. 20(6B), 4571–4578 (2000).
   PubMedGoogle Scholar
• Garcia del Muro X, Torregrosa A, Munoz J et al. Prognostic value of the expression of E-cadherin and beta-catenin in bladder cancer. Eur. J. Cancer 36(3), 357–362 (2000).
   PubMed Web of Science ®Google Scholar
• Slaton JW, Karashima T, Perrotte P et al. Treatment with low-dose interferon-alpha restores the balance between matrix metalloproteinase-9 and E-cadherin expression in human transitional cell carcinoma of the bladder. Clin. Cancer Res. 7(9), 2840–2853 (2001).
   PubMed Web of Science ®Google Scholar
• Sugino T, Gorham H, Yoshida K et al. Progressive loss of CD44 gene expression in invasive bladder cancer. Am. J. Pathol. 149, 873–882 (1996).
   PubMed Web of Science ®Google Scholar
• Lipponen P, Aaltoma S, Kosma VM, Ala-Opas M, Eskelinen M. Expression of CD44 standard and variant-v6 proteins in transitional cell bladder tumours and their relation to prognosis during a longterm follow-up. J. Pathol. 186, 157–164 (1998).
   PubMed Web of Science ®Google Scholar
• Marhaba R, Zoller M. CD44 in cancer progression: adhesion, migration and growth regulation. J. Mol. Histol. 35(3), 211–231 (2004).
   PubMed Web of Science ®Google Scholar
• Heider KH, Kuthan H, Stehle G, Munzert G. CD44v6: a target for antibody-based cancer therapy. Cancer Immunol. Immunother. 53(7), 567–579 (2004).
   PubMed Web of Science ®Google Scholar
• Liebert M, Washington R, Stein J, Wedemeyer G, Grossman HB. Expression of the VLA β 1 integrin family in bladder cancer. Am. J. Pathol. 144, 1016–1022 (1994).
   PubMed Web of Science ®Google Scholar
• Liebert M, Wedemeyer G, Stein JA et al. The monoclonal antibody BQ16 identifies the alpha 6 beta 4 integrin on bladder cancer. Hybridoma 12, 67–80 (1993).
   PubMedGoogle Scholar
• Coussens LM, Fingleton B, Matrisian LM. Matrix metalloproteinase inhibitors and cancer: trials and tribulations. Science 295, 2387–2392 (2002).
   PubMed Web of Science ®Google Scholar
• Kanayama H. Matrix metalloproteinases and bladder cancer. J. Med. Invest. 48, 31–43 (2001).
   PubMedGoogle Scholar
• Hara I, Miyake H, Hara S et al. Significance of matrix metalloproteinases and tissue inhibitors of metalloproteinase expression in the recurrence of superficial transitional cell carcinoma of the bladder. J. Urol. 165, 1769–1772 (2001).
   PubMedGoogle Scholar
• Vihinen P, Kahari VM. Matrix metalloproteinases in cancer: prognostic markers and therapeutic targets. Int. J. Cancer 99, 157–166 (2002).
   PubMed Web of Science ®Google Scholar
• Nutt JE, Mellon JK, Qureshi K, Lunec J. Matrix metalloproteinase-1 is induced by epidermal growth factor in human bladder tumour cell lines and is detectable in urine of patients with bladder tumours. Br. J. Cancer. 78, 215–220 (1998).
   PubMedGoogle Scholar
• Miyake H, Yoshimura K, Hara I, Eto H, Arakawa S, Kamidono S. Basic fibroblast growth factor regulates matrix metalloproteinase production and in vitro invasiveness in human bladder cancer cell lines. J. Urol. 157, 2351–2355 (1997).
   PubMedGoogle Scholar
• Yano A, Nakamoto T, Hashimoto K, Usui T. Localisation and expression of tissue inhibitor of metalloproteinase-1 in human urothelial cancer. J. Urol. 167, 729–734 (2002).
   PubMedGoogle Scholar
• Heppner Goss KJ, Brown LM, Matrisian LM. Differing effects of endogenous and synthetic inhibitors of metalloproteinases on intestinal tumorigenesis. Int. J. Cancer 78, 629–635 (1998).
   PubMedGoogle Scholar
• Bergers G, Javaherian K, Lo KM, Folkman J, Hanahan D. Effects of angiogenesis inhibitors on multistage carcinogenesis in mice. Science 284(5415), 808–812 (1999).
   PubMed Web of Science ®Google Scholar
• Pozzi A, Moberg PE, Miles LA, Wagner S, Soloway P, Gardner HA. Elevated matrix metalloprotease and angiostatin levels in integrin alpha 1 knockout mice cause reduced tumor vascularization. Proc. Natl Am. Soc. USA 97(5), 2202–2207 (2000).
   PubMed Web of Science ®Google Scholar
• McGarvey TW, Kariko K, Barnathan ES, Thomas J, Malkowicz SB. The expression of urokinase-related genes in superficial and invasive transitional bladder carcinoma. Int. J. Oncol. 12, 175–180 (1998).
   PubMed Web of Science ®Google Scholar
• Hasui Y, Marutsuka K, Suzumiya J, Kitada S, Osada Y, Sumiyoshi A. The content of urokinase-type plasminogen activator as a prognostic factor in urinary bladder cancer. Int. J. Cancer 50, 871–873 (1992).
   PubMed Web of Science ®Google Scholar
• Nakanishi K, Kawai T, Torikata C, Aurues T, Ikeda T. Urokinase-type plasminogen activator, its inhibitor, and its receptor in patients with upper urinary tract carcinoma. Cancer 82, 724–732 (1998).
   PubMedGoogle Scholar
• Alonso DF, Tejera AM, Farias EF, Bal de Kier Joffe E, Gomez DE. Inhibition of mammary tumor cell adhesion, migration, and invasion by the selective synthetic urokinase inhibitor B428. AntiCancer Res. 18(6A), 4499–4504 (1998).
   PubMed Web of Science ®Google Scholar
• Weidle UH, Konig B. Urokinase receptor antagonists: novel agents for the treatment of cancer. Expert Opin. Investig. Drugs 7(3), 391–403 (1998).
   PubMedGoogle Scholar
• Setyono-Han B, Sturzebecher J, Schmalix WA et al. Suppression of rat breast cancer metastasis and reduction of primary tumour growth by the small synthetic urokinase inhibitor WX-UK1. Thromb. Haemost. 93(4), 779–786 (2005).
   PubMed Web of Science ®Google Scholar
• Oliver RTD, Harland SJ, Leahy MG. Chemotherapy in urology, In: Comprehesive Urology. Weiss RM, George NJR, O’Reilly PH (Eds). Mosby International Ltd, 678–681 (2001).
   Google Scholar
• Cruz MRS, Sasse E, Sasse L, Clark L, Clark O. Adjuvant chemotherapy for muscle invasive bladder cancer: a systematic review and meta-analysis. 2005 ASCO Annual Meeting Proceedings. J. Clin. Oncology 23(16S), 4733 (2005).
   Google Scholar
• Levine AM, Quinn I, Gorospe G, Lenz HJ, Tulpurle A. Phase I trial of anti-sense oligonucleotide vascular endothelial growth factor (VEGF-AS, Veglin) in patients with relapsed and refractory malignancies. 2004 ASCO Annual Meeting Proceedings. J. Clin. Oncology 22(14S), 3008 (2004).
   Google Scholar